President and Chairman of the Board of Echo Therapeutics. Based on the positive results that we have our first indication of continuous glucose monitoring provided in the ICU demonstrated a continuous monitoring of lactate is a logical extension of our research efforts. Initiation of this program demonstrates the robust platform provides our technology far beyond the hospital and diabetes markets. Results of our ex – vivo testing strongly suggest that we can expect to effectively monitor lactate thresholds using our transdermal biosensor technology. Thanks to our years of experience in advanced skin permeation technology, we begin additional programs in the coming year, vary a significant pipeline of both transdermal biosensors and needle-free topical and systemic drugs.
For more information about APP Pharmaceuticals.. APP plans deferoxamine mesylate in the fourth quarter of 2009 , which will be further expanded the company to start the critical care product line.About APP Pharmaceuticals,APP Pharmaceuticals is a fully integrated pharmaceutical company that develops, manufactures and markets injectable pharmaceutical products with a focus on the oncology, anti-infective, anesthetic / analgesic and critical care markets. The company offers one of the broadest product portfolios in hospitals, care facilities, alternate care sites and clinics in North America and manufactures a comprehensive range of dosage formulations. Fresenius Kabi Pharmaceuticals Holding, a wholly owned subsidiary of Fresenius Kabi AG, acquired APP Pharmaceuticals, September 2008. Continue reading